Calamos Wealth Management LLC Trims Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Calamos Wealth Management LLC cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,289 shares of the medical research company’s stock after selling 287 shares during the quarter. Calamos Wealth Management LLC’s holdings in IQVIA were worth $7,462,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in IQV. Team Hewins LLC boosted its stake in IQVIA by 5.0% during the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares in the last quarter. Covestor Ltd grew its holdings in IQVIA by 45.3% during the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the period. Jag Capital Management LLC raised its position in IQVIA by 0.4% in the fourth quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock worth $2,638,000 after acquiring an additional 49 shares in the last quarter. Continuum Advisory LLC lifted its holdings in IQVIA by 3.3% in the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 49 shares during the last quarter. Finally, Raleigh Capital Management Inc. boosted its position in shares of IQVIA by 4.5% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company’s stock valued at $268,000 after purchasing an additional 50 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research reports. UBS Group raised their target price on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Evercore ISI increased their price target on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. The Goldman Sachs Group began coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective on the stock. Finally, Barclays raised their target price on shares of IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $265.67.

IQVIA Stock Up 1.6 %

IQV stock traded up $3.97 during mid-day trading on Friday, hitting $248.93. The stock had a trading volume of 557,532 shares, compared to its average volume of 1,065,940. The stock has a market capitalization of $45.38 billion, a price-to-earnings ratio of 34.01, a PEG ratio of 2.26 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a fifty day moving average of $227.79 and a 200 day moving average of $233.19.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.22 earnings per share. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.24 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.